



Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release

<u>Gabrielle Leclercq</u>¹, Helene Haegel¹, Anneliese Schneider¹, Estelle Marrer-Berger², Antje Walz², Christophe Boetsch², Vesna Pulko³, Cristiano Ferlini³, Christian Klein³

¹Pharmaceutical Sciences, Roche Innovation Center Zurich, Schlieren, Switzerland

²Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland

sitc

³ Oncology Discovery and Translational Area, Roche Innovation Center Zurich, Schlieren, Switzerland



Society for Immunotherapy of Cancer #SITC2020

Disclosure

I declare employment and patents with Roche.



Content of the presentation

- 1. Background:
 - T cell bispecific antibodies-related toxicity risks
 - Dasatinib mode of action
- 2. Results :
 - Dose-dependent and reversible effect of dasatinib
 - Dasatinib as an on-off switch for TCB-induced T cell activation and cytokine release
- 3. Take-home messages



On-target, off-tumor toxicity risks associated with T cell bispecific antibodies (TCBs)

Example of on-target off tumor toxicity risk associated to HLA-A2 WT1-TCB



Illustrations made with Biorender

1985

2020


Expression of tumor associated antigen on healthy cells could lead to unwanted T cell activation and potential tissue damage after treatment with TCB. Recognition of non-WT1 expressing cells presenting homologous peptide on HLA-A2 could lead to killing of healthy cells after treatment with HLA-A2 WT1-TCB.

35th Anniversary Annual Meeting & Pre-Conference Programs




#SITC2020

Proposed mode of action of dasatinib




Dasatinib prevents TCB-mediated target cell killing at pharmacologically active dose




The dose of dasatinib recommended for the patient is 100 mg Q.D. which leads

The blockade of TCB-mediated target cell killing by dasatinib is reversible





1 nM CEA-TCB

1 nM CEA-TCB




+ 100 nM dasatinib






Real time killing of MKN45 NucLightRed cells by CEA-TCB followed by Incucyte[®]. Last scan of 1st, 2nd, and 3rd stimulation, zoom 10x, phase and red, 400ms acquisition time.

Can dasatinib switch off TCB-activated T cells?




Dasatinib reduces T cell proliferation induced by HLA-A2 WT1-TCB in the presence of SKM-1 target cells

10 nM HLA-A2 WT1-TCB




Dasatinib stops T cell activation induced by HLA-A2 WT1-TCB in the presence of SKM-1 target cells




Expression of CD25 on CD4+ and CD8+ T cells was measured by flow cytometry at 24 hours and at 48 hours in the




Dasatinib stops cytokine release induced by HLA-A2 WT1-TCB in the presence of SKM-1 target cells



PBMCs were stimulated with 10 nM HLA-A2 WT-1-TCB in the presence of SKM-1 cells. Cytokines were detected in the supernatants using Luminex at 24 hours and at 48h in the presence and absence of dasatinib.




Does dasatinib prevent TCB-mediated target cell killing?




Dasatinib prevents target cell killing upon second TCB stimulation

10 nM HLA-A2 WT-1-TCB



Dasatinib switches off cytokine release by PBMCs upon second TCB stimulation



Cytokines are detected in the supernatant by Luminex 24 hours after second stimulation with 10 nM HLA-A2 WT-1-TCB in the presence and absence of dasatinib.

 10 nM HLA-A2 WT-1-TCB in the presence and absence of dasatinib.

 35th Anniversary Annual Meeting & Pre-Conference Programs

 Image: Site of the presence and absence of dasatinib.

 35th Anniversary Annual Meeting & Pre-Conference Programs

Take-home messages

It was shown that dasatinib:

- Is effective at pharmacological active dose (100 mg Q.D.) ٠
- Reversibly switches off TCB-activated T cells •
- Efficiently stops HLA-A2 WT1-TCB-induced T cell proliferation, activation and cytokine release ٠
- Efficiently prevents HLA-A2 WT1-TCB-induced target cell killing ٠
- Inhibits the release of IL-2, TNF- α and IFN- γ by activated T cells •

Dasatinib could be a promising mitigation strategy for off-tumor related toxicities or high grade cytokine release syndrome induced by T cell engaging therapies.

The *in vivo* proof-of concept study is on-going.



Acknowledgment



Hélène Haegel
Anneliese Schneider
Anna Maria Giusti
Estelle Marrer-Berger
Antje Walz
Christophe Boetsch



Prof. Alex Odermatt

1985

2020









Back-up slides







Society for Immunotherapy of Cancer

#SITC2020

Is T cell activation blockade with dasatinib reversible?



T cells are activated following first TCB stimulation (20 hours)



CD69 and CD25 expression on CD4+ and CD8+ T cell was measured by FACS at 24h. Data are shown as mean of 3 donors +/- SEM.

35th Anniversary Annual Meeting & Pre-Conference Programs (sic) #SITC2020

Dasatinib prevents TCB-induced T cell degranulation

